The men were randomly given a fixed combination of saw palmetto extract and stinging nettle root or the 5-alpha-reductase inhibitor
The decrease in PSA in the Se-SM group shows that prophylaxis due to the Se-SM combination may be as effective as 5-alpha-reductase inhibitor
treatment (Tindall and Rittmaster, 2008).
Exclusion criteria included a history of invasive BPH treatment, recent treatment with either an alpha-blocker or a 5-alpha-reductase inhibitor
; recent phytotherapy, including saw palmetto; and a history of prostate or bladder cancer.
Clinical usefulness of serum prostate specific antigen for the detection of prostate cancer is preserved in men receiving the dual 5-alpha-reductase inhibitor
Treatment of benign prostatic hyperplasia with 5-alpha-reductase inhibitor
: morphological changes in patients who fail to respond.
At the time of presentation, his medications included a 5-alpha-reductase inhibitor
(dutasteride) and his anti-Parkinsonian medications (levodopa and the dopamine agonist pramipexole).
Approximately half were randomly assigned to take the 5-alpha-reductase inhibitor
finasteride and half to take placebo for 7 years.
The Prostate Cancer Prevention Trial prospectively evaluated finasteride, a 5-alpha-reductase inhibitor
, as chemoprevention.
Just last year, some researchers in the United States said that their reevaluation of the research didn't come to the same conclusions, and wrote that all men should take a patent medicine 5-alpha-reductase inhibitor
to reduce their risk of prostate cancer.
Many of us will reach for an alpha-adrenergic antagonist or a 5-alpha-reductase inhibitor
as first-line therapy for patients with mild but annoying symptoms.
Dutasteride and finasteride, another 5-alpha-reductase inhibitor
, were shot down as prostate chemoprevention agents in December 2010 by the FDA's Oncologic Drugs Advisory Committee on the basis that the risk-benefit profile for either drug is not favorable when it is used to reduce the risk of prostate cancer.
A team led by Edinburgh University and University College London studied about 55,000 men in the UK, who had been prescribed 5-alpha-reductase inhibitors
over an 11-year period.